Expert Interview
Digging into the final analysis from the Phase 3 ALPINE trial of Zanubrutinib (BRUKINSA) for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Ticker(s): BGNEInstitution: City of Hope
- Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
- Manages 150 patients with lymphoma (1/2 are CD30+) and 10 patients with relapsed refractory CLL.
- Specializes in the treatment of lymphomas as well as stem cell transplantation and cellular immunotherapy; participates in multiple clinical trials in the areas of lymphoma, transplant and immunotherapy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
